Naurex presents 'compelling' data for depression drug GLYX-13
This article was originally published in Scrip
Executive Summary
Arizona's Naurex has presented detailed results from its Phase IIb trial of depression drug GLYX-13, which show that the product had a fast and significant effect in reducing depression symptoms, which was sustained over six weeks. The company confirmed that it will be going ahead with its planned Phase III trial at the beginning of 2015.
You may also be interested in...
J.P. Morgan Notebook Day 3: Biotech Feeling Government Shutdown, AstraZeneca, Denali, Allergan, Aptinyx, Sangamo
Daily round-up of news and notes from the 2019 J.P. Morgan Healthcare Conference in San Francisco: AstraZeneca's net prices set to slide in 2019; biotechs ponder disasters from government shutdown; Denali moves into gene therapy; Sangamo clarifies partnering strategy; and Scrip talks to Allergan and Aptinyx about upcoming NMDA data releases.
J.P. Morgan Notebook Day 3: Biotech Feeling Government Shutdown, AstraZeneca, Denali, Allergan, Aptinyx, Sangamo
Daily round-up of news and notes from the 2019 J.P. Morgan Healthcare Conference in San Francisco: AstraZeneca's net prices set to slide in 2019; biotechs ponder disasters from government shutdown; Denali moves into gene therapy; Sangamo clarifies partnering strategy; and Scrip talks to Allergan and Aptinyx about upcoming NMDA data releases.
Allergan Focuses On Aesthetics As Sales Dip For Dry Eye Leader Restasis
Allergan's second quarter exceeded expectations and full-year guidance was raised slightly, but while the aesthetics business grew, ophthalmology with a 9.4% Restasis decline was a notable outlier.